Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.50) by 18 percent. The company reported quarterly sales of $1.676 million which beat the analyst consensus estimate of $1.632 million by 2.70 percent. This is a 110.55 percent increase over sales of $796.000 thousand the same period last year.
Evoke Pharma Q4 2023 GAAP EPS $(0.59) Misses $(0.50) Estimate, Sales $1.676M Beat $1.632M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.